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INTRODUCTION
Patients with a history of allergic reaction to penicillin, but 
with no detectable specific IgE, are common and pose a dilem-
ma. The incidence of allergic reactions to drugs is difficult to 
determine. In 2001, the authors of a large review of the interna-
tional literature found adverse reactions to drugs in 1.8–15.1% 
of hospitalized patients.
1 Regarding penicillin, a retrospective 
study from 2004 that involved 3,375,162 patients who received 
a prescription for penicillin reported an allergy-like reaction in 
6,212 (0.18%).
2 The Danish Drug Administration has identified 
30 cases of fatal anaphylactic shock due to drugs in the Danish 
population of 5 million people from 1968 to 1990.
3 Of these 30 
fatal reactions, seven were caused by antibiotics: penicillin in 
four cases, ampicillin in two, and a sulfa drug in one.
In most European countries, the use of narrow-spectrum pen-
icillins has steadily decreased during the past decades. Although 
narrow-spectrum penicillins are still the most commonly sold 
antibiotics in Denmark and Sweden and are still used in Fin-
land, Ireland, the UK, Austria, Germany, and the Netherlands, 
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they are almost obsolete in other countries.
4 This may explain 
why several studies have found reactions to penicillin to be 
quite rare compared with reactions to, for example, cephalo-
sporins.
5,6
Genetic factors such as a family history of reactions to penicil-
lins may also play a role, as recently investigated.
7 The parenter-
al route of administration is thought to cause more allergic re-
actions.
8 Dosage and frequency of administration may also in-
fluence the incidence of reactions, but documentation is 
sparse.
Drug challenge is the only certain way to discriminate be-
tween patients with and without future risk for reactions to pen-
icillin. However, because of the potential for severe anaphylac-
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Purpose:  Patients with a history of allergic reaction to penicillin, but with no detectable specific IgE, are common and pose a dilemma. Challenge 
tests are considered to be the diagnostic gold standard. The aim of this study was to identify subgroups of patients with very low risk for reactions 
who could be safely tested using a more rapid and simple procedure.  Methods:  A total of 580 consecutively referred adult patients with a history 
of non-serious cutaneous allergic reactions to penicillin, but with no IgE, were challenged with therapeutic doses of penicillin V (phenoxymethylpen-
icillin), penicillin G (benzylpenicillin), or both.  Results:  Only 14 of 580 patients had a positive challenge test. In 11 of the 14, a reaction to challenge 
occurred within 2 hours, and none were anaphylactic. The year of the original reaction was known for 555 patients; a positive challenge was seen in 
only 0.4% of those with an original reaction >15 years before challenge, but in 4.6% of those with a more recent original reaction (P=0.001). Onset 
of a reaction within the first day of the original exposure was a predictive factor for a positive challenge (P=0.001) in patients challenged within 15 
years of the original reaction.  Conclusions:  Among suspected penicillin-allergic patients with non-severe skin reactions and no detectable specif-
ic IgE, the subgroup of patients who originally reacted more than 15 years previously had very low risk for reacting to a challenge. The risk was high-
er in patients with a more recent original reaction, especially if the symptoms had occurred within the first day of exposure.
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tic and other serious reactions, testing must be performed with 
caution. This makes testing demanding with respect to time and 
labor. The aim of this study was to identify subgroups of patients 
with very low risk for reactions who could be safely tested using 
a more rapid and simple procedure. 
MATERIALS AND METHODS
Patients
At our clinic, controlled challenges with penicillin are per-
formed in the majority of patients referred for suspected allergy 
(but no IgE) to penicillins. Exceptions are patients who decline 
this test and those who have had severe skin reactions such as 
exfolative or bullate reactions, or systemic reactions involving 
the liver or bone marrow. Most patients are referred by general 
practitioners, and a few come from other hospital departments, 
dentists, and private clinics. Doctors are usually aware of our 
challenge criteria, and thus selection takes place prior to refer-
ral. Using the hospital’s administrative system, we identified 
580 patients (444 females and 136 males) who had been chal-
lenged with penicillin V (phenoxymethylpenicillin), penicillin 
G (benzylpenicillin), or both, between January 1, 2001 and De-
cember 31, 2006. Clinical data were collected from the patients’ 
medical notes. The patients ranged in age from 13 to 87 years, 
with a mean of 39 years (women, 38.9 years; men, 39.2 years).
Approval for data collection and storage was obtained from 
the Danish Data Protection Agency (2009-41-3271). The region-
al ethics committee did not find it necessary to approve this ret-
rospective study.
Diagnosis
All patients were interviewed by a physician before beginning 
the challenge. Patients with a history suggestive of an allergic 
reaction to penicillin (skin rash or angioedema), but no history 
of other systemic reactions or severe skin reactions as aforemen-
tioned, were offered the challenge. All patients were tested for 
the presence of relevant specific IgE in serum, and the patients 
testing positive who did not receive the challenge because of a 
high suspicion of allergy were not included in the study. An Im-
munoCAP fluorescence enzyme immunoassay system (Phadia, 
Uppsala, Sweden) was used for IgE measurements. Standard 
analyses included those for the allergens penicilloyl G, penicil-
loyl V, amoxicilloyl, and ampicilloyl, with a cut-off value of 0.35 
kU
A/L. All patients with no detectable IgE were offered a chal-
lenge with penicillin V, penicillin G, or both.
After informed consent was obtained, the patients were chal-
lenged with the penicillin suspected of having caused the origi-
nal reaction. For cases in which this was unknown, penicillin V, 
penicillin G, or both were chosen, depending on the route of 
administration. Challenges were performed in the ward, which 
was equipped with facilities for treatment of anaphylaxis, and 
patients were observed for at least 2 hours after the last dose. 
An incremental procedure was applied, with the administra-
tion of 1:100, 1:10, and full therapeutic (1 million IE) doses at 
intervals of 30 to 60 minutes. The dose titration with intrave-
nous penicillin G to the full dose was most often followed by a 
full oral provocation dose of penicillin V. No placebo was in-
cluded, as objective symptoms were necessary for a positive 
challenge. Patients were instructed to report back with any sus-
picion of late reactions within the days after the challenge.
Statistical methods
Statistical analyses were performed using SPSS version 15.0 
software (SPSS, Inc., Chicago, IL, USA). The 95% confidence in-
tervals were determined from the Poisson distribution, and P 
values were calculated using a chi-squared or Fisher’s exact test 
for 2×2 tables. Values of P<0.05 were considered to indicate 
significance.
 
RESULTS
During the study period, challenges were performed in 580 
patients, and 14 patients (2.4%) (7 females and 7 males) had 
positive reactions (Table 1). Of these, 11 reactions occurred at 
the clinic and three were delayed, appearing after the patient 
had returned home. None fulfilled the criteria of an anaphylac-
tic reaction.
The time between the original reaction and the challenge and 
the age at the time of the original reaction were analyzed. Posi-
tive challenges appeared to occur more often in those with a 
more recent original reaction (Fig. 1), but were more evenly dis-
tributed according to age (Fig. 2). The median time interval be-
tween the original reaction and the challenge was 15 years. 
Among the 280 patients who had experienced an original reac-
tion within the previous 15 years, 13 (4.6%) had a positive chal-
lenge. In contrast, only one (0.4%) of the 275 patients with an 
original reaction that had occurred more than 15 years earlier 
showed a positive reaction to the challenge (P=0.001).
The aim of this investigation was to identify predictive param-
eters for the outcome of the challenge, and the time between 
the original reaction and the challenge appeared to be a strong 
predictive factor. Therefore, the subgroup of patients with a re-
ported original reaction within the 15 years prior to the chal-
lenge was chosen for subsequent analyses.
Seventy-nine of the 280 patients recalled with certainty having 
received penicillin V before the original reaction. Of these, 7.1% 
(6/79) had a positive challenge. Among the patients who report-
ed symptom onset within 1 day after the original dose, 11% 
(7/64) reacted positively to the challenge, in contrast to only 1% 
(1/137) of those reporting a later reaction (P=0.001) (Table 2). 
Itching was investigated separately, and none of the patients 
who reported the absence of an itching reaction had a positive 
challenge result (Table 3). However, a large portion of the pa-
tients did not remember whether there had been itching. Eight Holm et al.
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(6.1%) of 134 patients with a generalized rash reacted to the 
challenge, compared with one (2.8%) of 36 patients with local-
ized reactions (P=0.29). Of the 280 patients with a more recent 
original reaction, 108 did not report a rash or did not remember 
the extent of it. For the 135 patients with information about the 
duration of the original reaction, no significant difference in re-
action rate was found between those with symptoms lasting 0–2 
days and those with more long-lasting symptoms. A history of 
allergy to penicillin in first-line relatives showed no significant 
correlation with the challenge outcome. 
DISCUSSION
The diagnosis of allergy to penicillin is based on clinical histo-
ry and the results from IgE antibody measurements and skin 
tests. When these results are not in accordance, a challenge test 
is necessary for diagnosis. Standardized skin test material has 
not been available for several years, and skin testing was not 
performed in the present cohort. A recent study investigating 
non-immediate reactions in children found skin testing to be of 
limited value in this type of reaction.
9 The intention of the chal-
lenge test in the study analyzed here was to identify severe and 
Table 1.  Characteristics of the 14 patients with positive challenge to penicillin
Patient
Age 
(yr)
Original reaction Challenge reaction
Antibiotic Timing Symptoms
Interval 
from 
original 
reaction 
(yr)
Antibiotic (final dose)
Interval 
from 
last 
dose 
(hr)
Symptoms
Female 69 Unknown 
penicillin
Unknown Macular, red, confluent, itch-
ing, red rash on the trunk 
0 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
8 Itching in groin and on thighs with 
a burning sensation in the skin
Male 25 Unknown 
penicillin
Unknown Unspecified rash on trunk 
and face
10 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
6 Rash, swelling, and itching on scro-
tum and in groin
Female 32 Pivampicillin Unknown Unspecified rash and swell-
ing in mouth and face
10 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
1 Sensation of swelling of tongue 
and lips; challenge continued, later 
reported rash
Female 42 Penicillin V Duration 2 days Unspecified rash and swell-
ing in face
1 Penicillin G 
(100,000 IU)
<1 Flushing of face, swelling of hands
Female 24 Unknown 
penicillin
Unknown Gastrointestinal symptoms 
and unspecified rash
11 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
1 Urticaria on arms and shoulders, 
generalized itching, flushing of face 
Female 38 Unknown 
penicillin
Appeared 3 days 
after first dose
Maculopapular, itching rash 
on trunk
2 Penicillin V 
(1,000,000 IU)
1 Itch, red papules on neck and arms
Male 54 Penicillin V 
and erythro-
mycin
Appeared 1 day 
after first dose
Generalized, unspecified, 
itching rash
0 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
2 Urticaria and flushing of face
Male 55 Unknown 
penicillin
Appeared 1 day 
after first dose, 
lasted 4 days
Generalized urticaria, itching 1 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
2 Itching rash (unspecified)
Male 37 Penicillin V Appeared 1 day 
after first dose, 
lasted 1 day
Generalized urticaria sparing 
the trunk and swelling of lips
2 Penicillin G 
(100,000 IU)
1 Urticaria
Male 45 Penicillin V Appeared same 
day as first dose
Generalized urticaria and 
swelling of face
0 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
4 Urticaria
Male 5 Unknown 
penicillin
Unknown Generalized urticaria 36 Penicillin V 
(1,000,000 IU)
4 Itching and swelling
Male 18 Penicillin V Appeared same 
day as first dose
White, itching rash without 
papules
0 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
2 Sneezing, rhinitis, and urticaria
Female 25 Penicillin V Appeared same 
day as first dose, 
lasted 2 days
Small, red, itching macules 
covering whole body
2 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
3 Itching on scalp and neck
Female 28 Amoxicillin Appeared 1 day 
after first dose, 
lasted 7 days
Generalized red, itching rash 1 Penicillin V and G 
(1,000,000 + 1,000,000 IU)
6 Partly confluent rash on trunk of 
body, not itchingPenicillin Challenge AAIR 
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anaphylactic reactors among the referred patients, and thus the 
test included only one or two full doses, and not an entire treat-
ment period. As patient selection in the study analyzed here 
was not limited to only those with a clear history of an immedi-
ate reaction, it is possible that some late reactions might have 
been missed. This could explain why our study, despite not us-
ing skin tests, found a low number of positive challenges com-
pared with other studies. Another explanation could be a ten-
dency toward selecting patients with milder reactions prior to 
referral.
The suspected rate of allergy to penicillin varies among differ-
ent populations and different geographical locations, and the 
same appears to be true for the percentage of challenge-posi-
tive patients with no IgE sensitization. The present study repre-
sents one of the largest series of standardized challenge testing 
in suspected penicillin-allergic patients and allows for more 
conclusions regarding the possible risks and predictive factors 
for challenge testing.
Based on the data from this study, a patient with a history of a 
mild reaction to penicillin that occurred more than 15 years pre-
viously and with no detectable serum IgE antibodies to penicil-
lin V, penicillin G, amoxicillin, or ampicillin would have only a 
0.4% risk for reacting when given penicillin V or G in a clinical 
setting. In another study that included adult patients and chal-
lenge testing at a time closer to the original reaction, the mean 
age at the original reaction did not differ between patients with 
a positive challenge and those with a negative challenge.
10 How-
ever, as in our study, the time interval between the original re-
action and the challenge showed a significant difference be-
tween the positive and negative reactors, with a mean of 385 
days for positive outcomes compared with 769 days for nega-
tive outcomes. Thus, the time span from the original reaction to 
the challenge may be a stronger predictive factor than patient 
age at the original reaction. Therefore, we agree that much ear-
lier reactions to penicillin are unlikely to be confirmed at chal-
lenge, as recently suggested.
10
Two prospective studies found incidences of 8.4% and 7.6% 
positive challenges within a skin test-negative population of pa-
tients with a history of a physician-diagnosed reaction.
11,12 One 
reason for the higher reaction rates in those studies compared 
Table 2.  Relationship between symptom onset and the result of penicillin V or 
G challenge in the subgroup of patients with reported reactions within the pre-
vious 15 years
Onset of symptoms at original reaction
Reaction to challenge with 
penicillin G or V 
No Yes All
% Positive 
(95% CI)
During treatment, ≤1 day after first dose 57 7 64 11.0 (4.4–23)
During treatment, >1 day after first dose 103 1 104 1.0 (0.0–5.4)
After last dose 33 0 33 0.0 (0.0–11)
Unknown timing 74 5 79 6.3 (2.1–15)
All 267 13 280 4.6 (2.5–7.9)
95% CI, 95% confidence interval.
P=0.001 for onset within 1 day vs. later.
Table 3.  Relationship between itching in the original reaction and the result of 
penicillin V or G challenge in the subgroup of patients with reported reactions 
within the previous 15 years
Itching at original reaction
Reaction to challenge with 
penicillin G or V 
No Yes All
% Positive 
(95% CI)
No 24 0 24 0.0 (0.0–15)
Yes 114 8 122 6.6 (2.8–13)
Unknown 129 5 134 3.7 (1.2–8.7)
All 267 13 280 4.6 (2.5–7.9)
95% CI, 95% confidence interval.
P=0.23 for itching vs. no itching.
Fig. 1.  Challenge outcomes according to the time interval between the original 
reaction and the challenge test.
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with ours could be that all of the patients in the two earlier stud-
ies were challenged within 15 years of their original reaction, 
and most within a much shorter time span. Another study from 
2002, which included only skin test-negative patients with no 
detectable specific IgE, found 55% of 89 patients to be positive 
on challenge with β-lactams.
13 All of the patients in that study 
originally reacted within 1 hour after drug administration, and 
patients with an original reaction that occurred more than 15 
years prior to the study were not included. Our results indicate 
that a short interval between the initiation of exposure and the 
reaction is an important predictor for a positive challenge; an 
original reaction occurring on the first day of exposure in-
creased the risk for a positive challenge more than 10-fold.
A large number of patients who believe they are allergic to 
penicillin do not have a reaction upon challenge with penicil-
lin. This could be due to various possible reasons, including (1) 
the original reaction was not an allergic reaction; (2) the original 
reaction was to another drug administered at the same time; (3) 
the original reaction was to another drug, but was recalled as 
penicillin; or (4) the patient became tolerant to penicillin. It is 
known that the level of specific IgE to penicillin decreases over 
time with no exposure.
14,15 The much lower rate of allergy in our 
patients who originally reacted more than 15 years earlier sug-
gests that the patients allergic to penicillin could outgrow their 
allergy, but not until after the level of specific IgE becomes un-
detectable. We did not perform systematic follow-ups, but have 
not been contacted by any patients who reacted when reintro-
duced to penicillin at a later date, although a recent review 
found re-sensitization rates of 0.9% to 27.9%.
16
Even though more females were tested in our study, an equal 
number of males and females responded positively to the chal-
lenge. In Denmark, women had 47% more contacts with gener-
al practitioners and received 37% more defined daily doses of 
anti-infectious drugs (Anatomical Therapeutic Chemical Clas-
sification, ATC group J) than did men in 2005.
17 The more fre-
quent exposure to antibiotics might have caused a higher fre-
quency of allergic women, but this was not confirmed in our 
study, perhaps because of the small number of positives.
In conclusion, the data from this study suggest that patients 
with an original reaction more than 15 years previously, with-
out a history of serious rash or systemic reactions, and with no 
specific IgE can be safely challenged with penicillin in a setting 
with treatment for anaphylaxis at hand, but without titration of 
doses and without intravenous access. The time of symptom 
onset gave a good indication of the outcome of the challenge in 
patients with an original reaction within the previous 15 years. 
Furthermore, in this subgroup, no positive challenges were ob-
served in patients reporting the original reaction to be without 
itch. However, this information was often unavailable in cases 
with a long time span between reaction and testing. To increase 
our knowledge, a standardized and more detailed case history 
and less delay in patient referral are needed in future prospec-
tive studies.
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